Novo Nordisk recently informed NBDF that they are experiencing a temporary shortage of their product Rebinyn®, specifically in the 3,000 IU vial size. Rebinyn is a recombinant factor IX extended half-life therapy for the treatment of hemophilia B.
It is indicated for the on-demand treatment and control of bleeding episodes and the management of bleeding around surgery. It is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes.
The shortage will result in an intermittent supply for the next couple of months. However, the company indicated that it can maintain overall supply of the other vial sizes, including 500 IU,1,000 IU, 2,000 IU. The available vial sizes can be used in combination to equal the needed dose size that would normally be achieved through the 3,000 IU vial.
Novo Nordisk is working towards reestablishing a consistent supply of 3,000 IU vials of Rebinyn. In the meantime, please contact your healthcare provider with any questions or concerns about the shortage and your care. You can also contact Novo Nordisk Customer Care by calling 1.800.727.6500.
Read the full prescribing information for Rebinyn.
Source: Novo Nordisk
